Akari Therapeutics PLC expected to post a loss of $1.40 a share - Earnings Preview
Akari Therapeutics PLC <AKTX.OQ> expected to post a loss of $1.40 a share - Earnings Preview
Akari Therapeutics PLC AKTX.OQ AKTX.O is expected to report resultson August 11 (estimated) for the period ending June 30 2026
LSEG's mean analyst estimate for Akari Therapeutics PLC is for a loss of $1.40 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Akari Therapeutics PLC is $30.00, about 271.3% above its last closing price of $8.08
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2026 | -1.33 | -1.38 | -1.57 | Missed | -14 |
Dec. 31 2026 | -1.15 | -1.50 | 0.00 | Beat | 100 |
Sep. 30 2025 | -1.99 | -3.07 | 0.00 | Beat | 100 |
Jun. 30 2025 | -4.58 | -4.60 | 0.00 | Beat | 100 |
| |||||
|
This summary was machine generated August 7 at 20:57 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Akari Therapeutics
See all newsBrief: Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity In Urothelial Cancer Preclinical Models
UK's Akari Therapeutics Q2 net loss widens on higher R&D for AKTX-101
Akari Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary
Akari Therapeutics PLC expected to post a loss of $1.40 a share - Earnings Preview
Brief: Akari Therapeutics Enters Strategic Research Collaboration With Whitehawk Therapeutics